TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Clover Biopharmaceuticals Ltd. ( (HK:2197) ) has provided an announcement.
Clover Biopharmaceuticals Ltd. announced its interim results for the six months ended June 30, 2025, reporting a decrease in cash and bank balances due to loan repayments and ongoing R&D investments. Despite a reduction in expenses and improved operational efficiency, the company recorded a loss of RMB101.3 million, attributed to the absence of non-recurring income from the previous year.
The most recent analyst rating on (HK:2197) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Clover Biopharmaceuticals Ltd. stock, see the HK:2197 Stock Forecast page.
More about Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals Ltd. is a company operating in the biopharmaceutical industry, primarily focusing on the development and commercialization of vaccines and biologics, with a particular emphasis on respiratory vaccine candidates.
Average Trading Volume: 7,299,281
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.14B
See more data about 2197 stock on TipRanks’ Stock Analysis page.